A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of KL340399 Intratumoral in Patients with Advanced Solid Tumors
Latest Information Update: 11 Dec 2024
Price :
$35 *
At a glance
- Drugs KL 340399 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 09 Dec 2024 Planned End Date changed from 30 Aug 2024 to 30 Jun 2025.
- 09 Dec 2024 Planned primary completion date changed from 30 Aug 2024 to 30 Jun 2025.
- 27 Sep 2022 New trial record